Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
Kutsch N, Pallasch C, Decker T, Hebart H, Chow KU, Graeven U, Kisro J, Kroeber A, Tausch E, Fischer K, Fink AM, Wendtner CM, Ritgen M, Stilgenbauer S, Zhang D, Li B, Jürgensmeier JM, Rajakumaraswamy N, Bhargava P, Hallek M, Eichhorst B.
Kutsch N, et al. Among authors: jurgensmeier jm.
Hemasphere. 2022 May 25;6(6):e729. doi: 10.1097/HS9.0000000000000729. eCollection 2022 Jun.
Hemasphere. 2022.
PMID: 35747845
Free PMC article.
No abstract available.